173 related articles for article (PubMed ID: 12110370)
1. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
3. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
4. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
Ramamoorthy Y; Tyndale RF; Sellers EM
Pharmacogenetics; 2001 Aug; 11(6):477-87. PubMed ID: 11505218
[TBL] [Abstract][Full Text] [Related]
6. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
[TBL] [Abstract][Full Text] [Related]
7. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
8. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
Steuer AE; Schmidhauser C; Tingelhoff EH; Schmid Y; Rickli A; Kraemer T; Liechti ME
PLoS One; 2016; 11(3):e0150955. PubMed ID: 26967321
[TBL] [Abstract][Full Text] [Related]
9. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6.
Lin LY; Di Stefano EW; Schmitz DA; Hsu L; Ellis SW; Lennard MS; Tucker GT; Cho AK
Drug Metab Dispos; 1997 Sep; 25(9):1059-64. PubMed ID: 9311621
[TBL] [Abstract][Full Text] [Related]
11. Ecstasy: pharmacodynamic and pharmacokinetic interactions.
Oesterheld JR; Armstrong SC; Cozza KL
Psychosomatics; 2004; 45(1):84-7. PubMed ID: 14709765
[TBL] [Abstract][Full Text] [Related]
12. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
Jornil J; Jensen KG; Larsen F; Linnet K
Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
[TBL] [Abstract][Full Text] [Related]
14. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats.
Malpass A; White JM; Irvine RJ; Somogyi AA; Bochner F
Pharmacol Biochem Behav; 1999 Sep; 64(1):29-34. PubMed ID: 10494994
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
Van LM; Hargreaves JA; Lennard MS; Tucker GT; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 Sep; 32(1):8-16. PubMed ID: 17574396
[TBL] [Abstract][Full Text] [Related]
16. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).
Tucker GT; Lennard MS; Ellis SW; Woods HF; Cho AK; Lin LY; Hiratsuka A; Schmitz DA; Chu TY
Biochem Pharmacol; 1994 Mar; 47(7):1151-6. PubMed ID: 7909223
[TBL] [Abstract][Full Text] [Related]
17. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by fluoxetine of cytochrome P450 2D6 activity.
Otton SV; Wu D; Joffe RT; Cheung SW; Sellers EM
Clin Pharmacol Ther; 1993 Apr; 53(4):401-9. PubMed ID: 8477556
[TBL] [Abstract][Full Text] [Related]
20. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
